Irreversibly inhibits EGF-stimulated autophosphorylation of tyrosine residues in the epidermal growth factor receptor (EGFR) in vivo (IC50=250-490pM) and blocks EGF-mediated growth.
Product Details
| Alternative Name: | EKI-785, N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-butynamide |
| |
| Formula: | C18H13BrN4O |
| |
| MW: | 381.2 |
| |
| CAS: | 194423-06-8 |
| |
| Purity: | ≥95% (HPLC) |
| |
| Appearance: | Off-white to yellow solid. |
| |
| Solubility: | Soluble in DMSO (200mg/ml). |
| |
| Shipping: | Ambient |
| |
| Long Term Storage: | -20°C |
| |
| Handling: | Protect from light. Packaged under inert gas. Hygroscopic. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785): C.M. Discafani, et al.; Biochem. Pharmacol.
57, 917 (1999),
Abstract;
